Adjuvant Systemic Immunotherapies for Resected Stage III Melanoma: A Single-Centre Retrospective Clinical Practice Review.

Int J Mol Sci · 2025 · PMC11765691 · PMID 39859464

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

These results did not reach statistical significance ( p -value 0.54) but are consistent with the outcomes reported in the landmark trials assessing both pembrolizumab and nivolumab as adjuvant therapies for Stage III melanoma [ 27 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.